INTRODUÇÃO
==========

O comprometimento da perfusão sanguínea dos membros inferiores na doença arterial periférica (DAP) constitui um evento de morbidade potencialmente elevada. Apesar do sucesso incialmente obtido pela angioplastia transluminal percutânea por balão (ATPB), a taxa de reestenose pode chegar a 60% em 1 ano[@B001]. O uso de stents convencionais (SC) apareceu como uma tentativa de reduzir essa complicação, com algum sucesso. No entanto, ainda se observa uma taxa de reestenose intra-stent (RIS) relativamente alta, entre 18 e 37%, em 1 ano após o tratamento com SC em segmento femoropoplíteo ([Figura 1](#gf01){ref-type="fig"})[@B002].

![Arteriografia pré-tratamento evidenciando reestenose intra-stent de aproximadamente 85% no segmento mais crítico, em transição femoropoplítea.](jvb-16-01-031-g01){#gf01}

Alternativas para o tratamento da RIS incluem a ATPB e o implante de novo SC, com resultados pouco satisfatórios, e o desenvolvimento de novas tecnologias, como a angioplastia com balões revestidos com drogas (BRD), mais notoriamente com paclitaxel, que apresenta efeito antiproliferativo na parede arterial.

O objetivo do estudo é avaliar a eficácia do uso dos BRD como opção de tratamento para a RIS, além da ocorrência de complicações decorrentes desse uso.

MÉTODOS
=======

Foi realizada análise de coorte retrospectiva de prontuários de pacientes submetidos a angioplastia transluminal percutânea de segmento femoropoplíteo entre 2012 e 2016. Foram selecionados 32 pacientes (19 do sexo masculino e 13 do sexo feminino) com idade entre 56 e 77 anos (média de 66,5 anos) que se adequavam aos critérios de inclusão propostos neste estudo: RIS superior a 50% (velocidade de pico sistólico \> 180 cm/s) há mais de 3 meses, claudicação leve a lesão tecidual pequena (Rutherford 2-5), pelo menos uma artéria de deságue até o pé e extensão da lesão menor que 27 cm. Os critérios de exclusão (todos utilizados no COPA CABANA Trial[@B003]) foram: mais de duas lesões simultâneas, fratura do stent, insucesso na recanalização da lesão, trombose aguda e lesão proximal sem tratamento prévio, além da participação do paciente em outros estudos similares.

O intervalo entre o procedimento primário e o diagnóstico e tratamento da RIS variou entre 6 meses e 5 anos. Vinte e quatro pacientes (75%) foram tratados com o BRD IN.PACT™ Admiral® (Medtronic®) e oito (25%), com o BRD Lutonix® (Bard®).

O sucesso técnico foi definido como estenose residual inferior a 30% da lesão alvo quando comparadas arteriografias intraoperatórias pré- e pós-angioplastia. Estenoses superiores a 30%, trombose aguda, embolia distal e dissecção foram considerados critérios para o insucesso técnico.

O procedimento foi considerado satisfatório quando se observou sucesso técnico e um índice de reestenose inferior a 50%, quando comparado o eco-Doppler colorido (EDC) pré-operatório aos realizados 30, 90 e 180 dias após a intervenção, como é a rotina do serviço, pelo mesmo profissional que realizou o procedimento no momento do diagnóstico de RIS. Foram avaliados também os sinais e sintomas (presença e intensidade da claudicação e dor em repouso, presença ou não de lesões tróficas de características isquêmicas em membros inferiores) demonstrados pelos pacientes, assim como as complicações apresentadas.

Não houve exclusões de participantes por perda de seguimento ou falta das informações necessárias ao estudo.

O trabalho obteve aprovação do Comitê de Ética em Pesquisa.

RESULTADOS
==========

A taxa de mortalidade do procedimento foi zero. O tempo de internação após o procedimento variou de 1 a 4 dias e ocorreram complicações no pós-operatório imediato em dois pacientes (hematoma não cirúrgico no sítio de punção e elevação de escórias nitrogenadas).

Após 6 meses de acompanhamento, todos os 32 pacientes referiram melhora ou cessação dos sintomas apresentados antes da intervenção com o BRD, além de experimentarem aumento das distâncias percorridas sem claudicação, cicatrização de lesões tróficas e ausência de dor em repouso nos membros inferiores ([Tabela 1](#t01){ref-type="table"}). Não foi necessária nenhuma amputação de grande porte (acima do tornozelo).

###### Modificação da sintomatologia apresentada ao longo do acompanhamento, seguindo os critérios de Rutherford (0 = condição pré-operatória).

              **Tempo**                              
  ----------- ------------ ------------ ------------ ------------
  **0**       \- (0%)      8 (25%)      11 (34,4%)   16 (50%)
  **1**       \- (0%)      11 (34,4%)   15 (46,9%)   13 (40,6%)
  **2**       7 (21,8%)    10 (31,2%)   4 (12,5%)    3 (9,4%)
  **3**       12 (37,5%)   \- (0%)      \- (0%)      \- (0%)
  **4**       8 (25%)      \- (0%)      \- (0%)      \- (0%)
  **5**       5 (15,7%)    3 (9,4%)     2 (6,2%)     \- (0%)
  **6**       \- (0%)      \- (0%)      \- (0%)      \- (0%)
  **Total**   32 (110%)    32 (110%)    32 (110%)    32 (110%)

Ao fim do acompanhamento, quatro pacientes (12,5%) apresentaram reestenose superior a 50%, sendo um (3,1%) aos 90 dias e três (9,4%) aos 180 dias após o EDC arterial, conferindo uma taxa de sucesso de 87,5% ao procedimento ([Tabela 2](#t02){ref-type="table"} e [Figura 2](#gf02){ref-type="fig"}).

###### Resultados referentes ao seguimento com 30, 90 e 180 dias após tratamento de reestenose intra-stent por avaliação com eco-Doppler colorido.

  **Resultados**                            
  ---------------- ----------- ------------ ------------
  **Sucesso**      32 (100%)   31 (96,9%)   28 (87,5%)
  **Insucesso**    0 (0%)      1 (3,1%)     4 (12,5%)

![Angioplastia por estenose intra-stent em um dos casos do estudo. (A) estenose extensa intra-stent; (B) imagem em zoom de área de oclusão na porção proximal do stent; (C) angioplastia com balão farmacológico; (D) controle final, com melhora das lesões prévias.](jvb-16-01-031-g02){#gf02}

DISCUSSÃO
=========

A superioridade dos BRD em relação aos SC já foi demonstrada em diversos estudos sobre angioplastia da artéria femoral superficial, com melhor perviedade primária e redução das intervenções em complicações[@B004]-[@B006]. Além da eficácia em termos de melhora dos sintomas, tempo livre de reintervenção e redução na taxa de amputações, foi demonstrada segurança similar na realização do procedimento, o que pode ser explicado pela semelhança da técnica entre os procedimentos.

Os resultados obtidos em nossa casuística são compatíveis com os principais estudos publicados sobre o tratamento da RIS com BRD[@B003],[@B007]. No entanto, ainda são poucos os estudos sobre o tema, e estes não apresentam resultados a longo prazo. No momento, existem alguns estudos em andamento investigando a eficácia dos BRD na RIS da artéria femoral superficial, se destacando o PLAISIR Study, o ISAR-PEBIS RCT e o PACUBA I RCT[@B003].

Outro ponto a ser considerado é a relação custo-benefício dos BRD se comparados à ATPB e aos SC. Há estudos sugerindo que os BRD são superiores[@B008].

Por se tratar de um estudo retrospectivo de curto prazo, com número limitado de pacientes, com alguns vieses (como acompanhamento por mais de um ultrassonografista ou variados tipos de stents), com avaliação não cega, sem adequada avaliação da qualidade de vida, dos custos e do impacto econômico, entendemos que serão necessários estudos prospectivos que nos permitam avaliar se o resultado superior a curto prazo pode ser reproduzido a médio e longo prazo, assim como a relação custo-benefício do BRD quando comparado a outros tipos de intervenção.

CONCLUSÃO
=========

A terapia da RIS com balão revestido com paclitaxel é factível e pode ser realizada com segurança (baixa incidência de complicações relativas ao método; mortalidade nula), demonstrando excelentes resultados a curto prazo.

Fonte de financiamento: Nenhuma.

O estudo foi realizado na Clínica Julio Peclat, Rio de Janeiro, RJ, Brasil.
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Background
==========

In-stent restenosis due to myointimal hyperplasia after angioplasty is common and limits long-term patency. Treatments using balloons coated with antiproliferative drugs may offer an alternative option for this pathology.

Objectives
==========

To demonstrate the efficacy and complications (death, major amputations, etc.) of drug-coated balloons for treatment of in-stent restenosis in femoropopliteal segments.

Methods
=======

This was a retrospective cohort study of 32 consecutive patients treated between 2012 and 2016 who underwent treatment to correct in-stent restenosis in the femoropopliteal segment using paclitaxel-coated balloons. The success rate was measured in terms of technical success and restenosis of less than 50% on Doppler ultrasonography at 30, 90, and 180 days after the procedure.

Results
=======

Four patients (12.5%) exhibited restenosis greater than 50%, one (3.1%) after 90 days and three (9.4%) after 180 days, equating to a success rate of 87.5% of procedures, and by 180 days all patients experienced improvement or cessation of the signs and/or symptoms they had presented prior to the procedure. There were no deaths and complications occurred in just 2 cases in the immediate postoperative period.

Conclusions
===========

Short-term results are promising, with reductions in the magnitude of restenosis and a low rate of complications. Further studies are needed that can demonstrate the long-term effects and the economic impacts in comparison to other procedures.

peripheral artery disease

balloon angioplasty

vascular graft restenosis

INTRODUCTION
============

Compromise to blood perfusion of the lower limbs in peripheral arterial disease (PAD) is an event of elevated potential morbidity. Although initial success rates after percutaneous transluminal balloon angioplasty (PTBA), restenosis rates can be as high as 60% within 1 year.[@B001] Conventional stents (CS) have been used to attempt to reduce rates of this complication, with a certain degree of success. However, rates of in-stent restenosis (ISR) are still relatively high, at 18 to 37% at 1 year after treatment with CS in femoropopliteal segments ([Figure 1](#gf0100){ref-type="fig"}).[@B002]

![Pretreatment arteriography showing in-stent restenosis of approximately 85% at the most critical point, at the femoropopliteal transition.](jvb-16-01-031-g01-en){#gf0100}

Treatment options for ISR include PTBA and placement of a new CS, with fairly unsatisfactory results, and newly developed technologies, such as drug-coated balloons (DCBs), of which the most well-known is coated with paclitaxel, which has antiproliferative effects on the artery wall.

The objectives of this study are to investigate the efficacy of using DCBs as a treatment option for ISR, and to analyze the occurrence of complications related to their use.

METHODS
=======

A retrospective analysis was conducted of the medical records of a cohort of patients who had been treated with percutaneous transluminal angioplasty of femoropopliteal segments between 2012 and 2016. The cohort comprised 32 patients (19 males and 13 females) aged from 56 to 77 years (mean: 66.5 years) who met the inclusion criteria proposed for the study: ISR greater than 50% (peak systolic velocity \> 180 cm/s) for more than 3 months, mild claudication, and minor tissue damage (Rutherford 2-5), at least one artery draining as far as the foot, and lesion length of less than 27 cm. The exclusion criteria (all of those used for the COPA CABANA Trial[@B003]) were as follows: more than two simultaneous lesions, stent fracture, failure to recanalize the lesion, acute thrombosis, and proximal lesion with no prior treatment, in addition to participation of patient in other similar studies.

Intervals between the primary procedure and diagnosis and treatment of ISR ranged from 6 months to 5 years. Twenty-four patients (75%) were treated with an IN.PACT™ Admiral® DCB (Medtronic®) and eight (25%), with a Lutonix® DCB (Bard®).

Technical success was defined as residual stenosis of the target lesion of less than 30%, based on comparison of pre-angioplasty and post-angioplasty intraoperative arteriographies. Greater than 30% stenosis, acute thrombosis, distal embolism, and dissection were all defined as technical failure.

The procedure was considered satisfactory when technical success was achieved and observed restenosis was less than 50%, based on comparison of preoperative color Doppler ultrasonography findings of examinations conducted with the same technique at 30, 90, and 180 days by the same professional who had conducted the examination in which ISR was detected, in accordance with routine procedure at the service. Patients' signs and symptoms (presence and intensity of claudication and of pain at rest, presence or absence of trophic ulcers with ischemic characteristics on the lower limbs) and any complications suffered were also analyzed.

None of the study participants were excluded because of loss to follow-up or because any of the information needed for the study was missing.

This study was granted Research Ethics Committee approval.

RESULTS
=======

The mortality rate of this procedure was zero. The length of postoperative hospital stay varied from 1 to 4 days and there were complications during the immediate postoperative period in two patients (non-surgical hematoma at the puncture site and elevated nitrogen retention).

At 6-month follow-up, all 32 patients reported that the symptoms that they had experienced before intervention with the DCB had either improved or disappeared and also reported increases in the distances they were able to walk without claudication, healing of trophic ulcers, and absence of lower limb pain at rest ([Table 1](#t0100){ref-type="table"}). No major amputations (above the ankle) were necessary.

###### Changes to symptoms during follow-up, graded according to the Rutherford criteria (0 = preoperative condition).

              **Time (days)**                             
  ----------- ----------------- ------------ ------------ ------------
  **0**       \- (0%)           8 (25%)      11 (34.4%)   16 (50%)
  **1**       \- (0%)           11 (34.4%)   15 (46.9%)   13 (40.6%)
  **2**       7 (21.8%)         10 (31.2%)   4 (12.5%)    3 (9.4%)
  **3**       12 (37.5%)        \- (0%)      \- (0%)      \- (0%)
  **4**       8 (25%)           \- (0%)      \- (0%)      \- (0%)
  **5**       5 (15.7%)         3 (9.4%)     2 (6.2%)     \- (0%)
  **6**       \- (0%)           \- (0%)      \- (0%)      \- (0%)
  **Total**   32 (110%)         32 (110%)    32 (110%)    32 (110%)

By the final follow-up appointment, four patients (12.5%) exhibited restenosis greater than 50%, one (3.1%) at 90 days and three (9.4%) at 180 days after the arterial color Doppler ultrasonography, equating to a success rate of 87.5% of procedures ([Table 2](#t0200){ref-type="table"} and [Figure 2](#gf0200){ref-type="fig"}).

###### Results at 30, 90, and 180 days follow-up after in treatment of in-stent restenosis, assessed with color Doppler ultrasound.

  **RESULTS**                            
  ------------- ----------- ------------ ------------
  **Success**   32 (100%)   31 (96.9%)   28 (87.5%)
  **Failure**   0 (0%)      1 (3.1%)     4 (12.5%)

![Angioplasty for in-stent stenosis in one of the cases in the study sample. (A) extensive in-stent stenosis; (B) zoomed image of the area of occlusion in the proximal portion of the stent; (C) pharmacological balloon angioplasty; (D) final control image, with improvement to earlier lesions.](jvb-16-01-031-g02-en){#gf0200}

DISCUSSION
==========

The superiority of DCBs in comparison to CS has already been shown in several studies investigating angioplasty of the superficial femoral artery, revealing better primary patency and reductions in rates of interventions because of complications.[@B004]-[@B006] In addition to improved efficacy in terms of improvement of symptoms, time free from reintervention, and reductions in amputation rates, studies have also shown that the procedures have similar levels of safety, which is understandable considering the similar techniques employed.

The results achieved in our sample of patients are compatible with those reported in published studies of ISR treatment using DCBs.[@B003],[@B007] However, so far there have been few studies investigating this subject and those that exist do not report long-term results.

There are currently a number of ongoing studies investigating the efficacy of DCBs for ISR in the superficial femoral artery, among which the PLAISIR Study, the ISAR-PEBIS RCT, and the PACUBA I RCT are of note.[@B003]

Another point of interest is the cost-benefit relationship offered by DCBs in comparison to PTBA and CS. There are studies that suggest that DCBs are better in this respect.[@B008]

This was a short-term retrospective study of a limited number of patients, in which some possible sources of bias, such as follow-up with more than one sonographer, varied types of stents, were not assessed blind, insufficient evaluation of quality of life, costs, and economic impact. Therefore, we are aware that prospective studies are needed to enable assessment of whether the superior short-term results can be reproduced over the medium and long term, and also to compare the cost-benefit profile of DCBs to those of other types of intervention.

CONCLUSIONS
===========

Treatment of ISR with paclitaxel-coated balloons is feasible, it can be performed safely (the incidence of complications related to the method was low and mortality was zero), and it demonstrates excellent short-term results.

Financial support: None.

The study was carried out at Clínica Julio Peclat, Rio de Janeiro, RJ, Brazil.
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